<SEC-DOCUMENT>0001558370-24-014184.txt : 20241104
<SEC-HEADER>0001558370-24-014184.hdr.sgml : 20241104
<ACCEPTANCE-DATETIME>20241104083023
ACCESSION NUMBER:		0001558370-24-014184
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20241104
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20241104
DATE AS OF CHANGE:		20241104

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NeuroBo Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001638287
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				472389984
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37809
		FILM NUMBER:		241420947

	BUSINESS ADDRESS:	
		STREET 1:		545 CONCORD AVENUE
		STREET 2:		SUITE 210
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02138
		BUSINESS PHONE:		(857) 702-9600

	MAIL ADDRESS:	
		STREET 1:		545 CONCORD AVENUE
		STREET 2:		SUITE 210
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02138

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Gemphire Therapeutics Inc.
		DATE OF NAME CHANGE:	20150331
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>nrbo-20241104x8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 10.8.0.95 -->
<!-- Based on: iXBRL 1.1 -->
<!-- Created on: 11/1/2024 9:40:04 PM -->
<!-- iXBRL Library version: 1.0.9027.2259 -->
<!-- iXBRL Service Job ID: b171f74e-373d-4d9f-ab7f-82b471d4f2be -->
<html xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:nrbo="http://www.neurobopharma.com/20241104" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance"><head><meta http-equiv="content-type" content="text/html"/><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric contextRef="Duration_11_4_2024_To_11_4_2024_0HM4nUvhIk6dfCUaU79l4A" name="dei:EntityCentralIndexKey" id="Tc_Q3E9bgYu3EmakLr16uCgFg_1_1">0001638287</ix:nonNumeric><ix:nonNumeric contextRef="Duration_11_4_2024_To_11_4_2024_0HM4nUvhIk6dfCUaU79l4A" name="dei:AmendmentFlag" id="Tc_D7wVMaGpRk-PWAP_nRb-TA_2_1">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="nrbo-20241104.xsd" xlink:type="simple"/></ix:references><ix:resources><xbrli:context id="Duration_11_4_2024_To_11_4_2024_0HM4nUvhIk6dfCUaU79l4A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-04</xbrli:startDate><xbrli:endDate>2024-11-04</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:52.71pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;border-bottom:1px solid #000000;border-top:2.25pt solid #000000;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><a id="_5b019b0d_66dd_414d_801e_127dc8d85a5c"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:18pt;font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:18pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">WASHINGTON, D.C. 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:18pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FORM </b><ix:nonNumeric contextRef="Duration_11_4_2024_To_11_4_2024_0HM4nUvhIk6dfCUaU79l4A" name="dei:DocumentType" id="Narr_9VkLvaFZTUas3CmLbb6X_w"><b style="font-weight:bold;">8-K</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">CURRENT REPORT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Date of Report (Date of earliest event reported): </b><ix:nonNumeric contextRef="Duration_11_4_2024_To_11_4_2024_0HM4nUvhIk6dfCUaU79l4A" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="Narr_gcPPrxnD-0-tDaq3TrbLsQ"><b style="font-weight:bold;">November 4, 2024</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="nrbo-20241104x8k001.jpg" alt="Graphic" style="display:inline-block;height:52.71pt;width:191pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:16pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_11_4_2024_To_11_4_2024_0HM4nUvhIk6dfCUaU79l4A" name="dei:EntityRegistrantName" id="Narr_HIy_5AwW-E-shKtXAv5_rw"><b style="font-weight:bold;">NEUROBO PHARMACEUTICALS, INC.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">(Exact name of Registrant as Specified in Its Charter)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><a id="_13452a04_9467_4692_bd89_690379252b8f"></a><a id="Tc_MPDdwdgAjkO9yuA8OUASZg_2_0"></a><a id="Tc_5ro0WA1N-067su_DNmCoNg_2_2"></a><a id="Tc_dvhqr7E9xEm5EhQgcoDaxw_2_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_11_4_2024_To_11_4_2024_0HM4nUvhIk6dfCUaU79l4A" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="Tc_yg5R0fhpUkG-XfwYIzXtCw_1_0"><b style="font-weight:bold;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_11_4_2024_To_11_4_2024_0HM4nUvhIk6dfCUaU79l4A" name="dei:EntityFileNumber" id="Tc_CZg63igVd0CHyAxJ7qND9w_1_2"><b style="font-weight:bold;">001-37809</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_11_4_2024_To_11_4_2024_0HM4nUvhIk6dfCUaU79l4A" name="dei:EntityTaxIdentificationNumber" id="Tc_GkPc3mDfLEu5B_Bx16S1cg_1_4"><b style="font-weight:bold;">47-2389984</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(State or other jurisdiction</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">of incorporation)</p></td><td style="vertical-align:top;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Commission</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">File Number)</p></td><td style="vertical-align:top;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(IRS Employer</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Identification No.)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><a id="_a03c4018_f776_4435_ac00_d380f9b56282"></a><a id="Tc_OW7uUBHfdU6ZYh90Bbxhkw_1_0"></a><a id="Tc_ZPdwE8Dfa062Vdqn1HrrEg_2_0"></a><a id="Tc_WZlDsabQ70GpgQkEsMk-Ng_2_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:49.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_11_4_2024_To_11_4_2024_0HM4nUvhIk6dfCUaU79l4A" name="dei:EntityAddressAddressLine1" id="Narr_dAJP1cQoE0WbF9LLtRBYiA"><b style="font-size:9pt;font-weight:bold;">545 Concord Avenue</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_11_4_2024_To_11_4_2024_0HM4nUvhIk6dfCUaU79l4A" name="dei:EntityAddressAddressLine2" id="Narr_VuyVD8I5LUqOZO3dsZSV8Q"><b style="font-size:9pt;font-weight:bold;">Suite 210</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_11_4_2024_To_11_4_2024_0HM4nUvhIk6dfCUaU79l4A" name="dei:EntityAddressCityOrTown" id="Narr_lHnbpQkYZkWr8wVE0k_cZA"><b style="font-size:9pt;font-weight:bold;">Cambridge</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_11_4_2024_To_11_4_2024_0HM4nUvhIk6dfCUaU79l4A" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="Narr_0XFEjWajuEaqinTDZaXvhg"><b style="font-size:9pt;font-weight:bold;">Massachusetts</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;"> </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_11_4_2024_To_11_4_2024_0HM4nUvhIk6dfCUaU79l4A" name="dei:EntityAddressPostalZipCode" id="Tc_nEFDXnC7dUqWU2B78DSbQA_1_2"><b style="font-size:9pt;font-weight:bold;">02138</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:49.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.27;text-align:center;margin:0pt;">(Address of principal executive offices)</p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.27;text-align:center;margin:0pt;">(Zip Code)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(</b><ix:nonNumeric contextRef="Duration_11_4_2024_To_11_4_2024_0HM4nUvhIk6dfCUaU79l4A" name="dei:CityAreaCode" id="Narr_4aIvJG5xDEKEo4JDGhG_ag"><b style="font-weight:bold;">857</b></ix:nonNumeric><b style="font-weight:bold;">) </b><ix:nonNumeric contextRef="Duration_11_4_2024_To_11_4_2024_0HM4nUvhIk6dfCUaU79l4A" name="dei:LocalPhoneNumber" id="Narr_wDyLcISaTE6yWlTHeVFrdg"><b style="font-weight:bold;">702-9600</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Registrant&#8217;s telephone number, including area code)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Not applicable</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Former name or former address, if changed since last report)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><a id="_e51ff3d8_d6f6_44c9_b338_8f565e4a1604"></a><a id="Tc_DWegsEHFXEKpwH5v1_2DDw_1_1"></a><a id="Tc_VqdFQXo3Z0Oa-jRO_yo3CA_2_1"></a><a id="Tc_TIiL_fTauUKW3NQbqsM_yQ_3_1"></a><a id="Tc_Jum9Wn7gO0eWe5A0r0RruQ_4_1"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:3.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:3.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_11_4_2024_To_11_4_2024_0HM4nUvhIk6dfCUaU79l4A" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="Tc_rwncbftdJEeAIp4yg3ncZA_1_0"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </p></td></tr><tr><td style="vertical-align:top;width:3.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_11_4_2024_To_11_4_2024_0HM4nUvhIk6dfCUaU79l4A" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="Tc_f82-05L_SU-RBso3sp46yg_2_0"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </p></td></tr><tr><td style="vertical-align:top;width:3.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_11_4_2024_To_11_4_2024_0HM4nUvhIk6dfCUaU79l4A" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="Tc_zo6R3wnmQ0-kz37bMrW8mw_3_0"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </p></td></tr><tr><td style="vertical-align:top;width:3.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_11_4_2024_To_11_4_2024_0HM4nUvhIk6dfCUaU79l4A" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="Tc_B4Zo1vC75EqOfgtiauhQSw_4_0"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Securities registered pursuant to Section 12(b) of the Act:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><a id="_0c311cdb_c736_4079_9d07_0deae2867d84"></a><a id="Tc_NPFyfqVBM06efaxUDLRNZw_1_0"></a><a id="Tc_v7jyh9i7cE6VLD0KZjEJ5A_1_2"></a><a id="Tc_0BE5Ytmvb0SXVIJ2lCZNOg_1_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:39.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:14.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:41.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:39.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Title of each class</p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:14.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Trading</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Symbol(s)</p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:41.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Name of each exchange on which registered</p></td></tr><tr><td style="vertical-align:top;width:39.74%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_11_4_2024_To_11_4_2024_0HM4nUvhIk6dfCUaU79l4A" name="dei:Security12bTitle" id="Tc_DdptIfPQkESOHD1gTmn7bA_2_0">Common Stock, par value $0.001 per share</ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:14.66%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_11_4_2024_To_11_4_2024_0HM4nUvhIk6dfCUaU79l4A" name="dei:TradingSymbol" id="Tc_Nj_Ts2jEbEGUFTGoyhDnGw_2_2">NRBO</ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:41.46%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_11_4_2024_To_11_4_2024_0HM4nUvhIk6dfCUaU79l4A" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="Tc_wwMg7O69a0-nCLrm6tCqNw_2_4">The Nasdaq Stock Market LLC</ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#8201;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#8201;240.12b-2 of this chapter). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Emerging growth company&#160;<ix:nonNumeric contextRef="Duration_11_4_2024_To_11_4_2024_0HM4nUvhIk6dfCUaU79l4A" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="Narr_aRattVQSsUiWBVcbqpQxWw"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;<span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;border-bottom:2.25pt solid #000000;border-top:1px solid #000000;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_f89fd4f8_2f2f_496f_8d37_ff2512096853"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Item 7.01.</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;</span></span><b style="font-weight:bold;">Regulation FD Disclosure.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On November 4, 2024, NeuroBo Pharmaceuticals, Inc. (the "Company") issued a press release announcing the completion of the last patient last visit in its two-part, Phase 2a clinical trial evaluating the efficacy and safety of DA-1241, a novel G-Protein-Coupled Receptor 119 (GPR119) agonist for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K (the &#8220;Report&#8221;) and incorporated herein by reference.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">Information contained on or accessible through any website reference in the press release is not part of, or incorporated by reference in, this Report, and the inclusion of such website addresses in this Report by incorporation by reference of the press release is as inactive textual references only.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">Exhibit 99.1 hereto contains forward-looking statements within the meaning of the federal securities laws. These forward-looking statements are based on current expectations and are not guarantees of future performance. Further, the forward-looking statements are subject to the limitations listed in Exhibit 99.1 and in the other reports of the Company filed with the Securities and Exchange Commission, including that actual events or results may differ materially from those in the forward-looking statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">The information in this Report, including Exhibit 99.1 hereto, is furnished pursuant to Item 7.01 and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing. The Company&#8217;s submission of this Report shall not be deemed an admission as to the materiality of any information required to be disclosed solely to satisfy the requirements of Regulation FD.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_7d664369_806c_4d73_ad4d_f0c38fb93ca7"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Item 9.01.</b></span><b style="font-weight:bold;">Financial Statements and Exhibits.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">(d) Exhibits</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:12.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:85.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:12.21%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exhibit<br/>Number</p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:85.72%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exhibit&#160;Description</p></td></tr><tr style="height:15.75pt;"><td style="vertical-align:top;width:12.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">99.1</p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="nrbo-20241104xex99d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Press Release dated November 4, 2024.</span></a></p></td></tr><tr style="height:15.75pt;"><td style="vertical-align:top;width:12.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">104</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cover Page Interactive Data File (embedded within Inline XBRL document).</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_fc032a76_8b43_4d19_8754_7cd42af3ee7c"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SIGNATURES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:48.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:3.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:45.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:48.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:49.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">NEUROBO PHARMACEUTICALS, INC.</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:21.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt -14pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:49.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:21.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt -14pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:49.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:21.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt -14pt;">Date: November 4, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By: </p></td><td style="vertical-align:bottom;width:45.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Hyung Heon Kim</p></td></tr><tr><td style="vertical-align:bottom;width:48.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:45.94%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Hyung Heon Kim</p></td></tr><tr><td style="vertical-align:bottom;width:48.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:45.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">President and Chief Executive Officer</i></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>nrbo-20241104xex99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.125.0--><!--Created on: 11/1/2024 09:40:03 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;">Exhibit 99.1</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="nrbo-20241104xex99d1001.jpg" alt="Graphic" style="display:inline-block;height:57.27pt;width:171.48pt;"></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-size:13pt;font-weight:bold;">NeuroBo Pharmaceuticals Completes Last Patient Last Visit in Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-style:italic;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><i style="font-style:italic;">Topline Data Readout From Part 1 and Part 2 Expected in December 2024</i></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-style:italic;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><b style="font-weight:bold;">CAMBRIDGE, Mass., November 4, 2024 &#8211; </b><b style="font-weight:bold;">NeuroBo Pharmaceuticals, Inc.</b><b style="font-weight:bold;"> </b>(Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced the completion of the last patient last visit in its two-part, Phase 2a clinical trial evaluating the efficacy and safety of DA-1241, a novel G-Protein-Coupled Receptor 119 (GPR119) agonist for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;">&#8220;Completion of patient dosing in the Phase 2a clinical trial of DA-1241, in patients with presumed MASH, marks an important milestone for this promising cardiometabolic asset, bringing us one step closer to the topline data readout from both Part 1 and Part 2 of the Phase 2a clinical trial expected in December of this year,&#8221; stated Hyung Heon Kim, President and Chief Executive Officer of NeuroBo. &#8220;As a reminder, Part 1 of this Phase 2a trial is exploring DA-1241 compared to placebo, while Part 2 is investigating the efficacy of DA-1241 in combination with sitagliptin, a DPP-4 inhibitor, which we believe will show synergistic effects compared to DA-1241, alone.<font style="font-family:'Arial','Helvetica','sans-serif';font-size:13.5pt;background:#f4f5f6;"> </font>In a previously reported Phase 1 study, DA-1241 was well tolerated in both healthy volunteers and individuals diagnosed with type 2 diabetes mellitus (T2DM). Based on the pre-clinical and clinical evidence, we maintain our belief that the distinctive mechanism of action DA-1241, which addresses the inflammation linked to MASH, will result in a safe and effective therapeutic option for this disease.&#8221; </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;">Each of the two parts of the Phase 2a trial of DA-1241 are designed to be 16-week, multicenter, randomized, double-blind, placebo-controlled, parallel clinical studies to evaluate the efficacy and safety of DA-1241 in subjects with presumed MASH. A total of 109 patients were randomized, while 95 patients completed the dosing. These patients were enrolled in either Part 1, which is exploring the efficacy of DA-1241 versus placebo, and randomized in a 1:2:1 ratio into 3 treatment groups: DA-1241 50 mg, DA-1241 100 mg or placebo, or into Part 2, which is exploring the efficacy of DA-1241 in combination with sitagliptin versus placebo, randomized in a 2:1 ratio into 2 treatment groups: DA-1241 100 mg/sitagliptin 100 mg or placebo. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;">For both Part 1 and Part 2, the primary endpoint is the change from baseline in alanine transaminase (ALT) levels at Week 16. Secondary efficacy endpoints include the proportion of subjects with normalization of ALT, absolute change in total cholesterol, low and high-density lipoprotein cholesterol, triglycerides, and free fatty acids from baseline, among others. Safety will be evaluated by monitoring adverse events (AEs) and serious adverse events (SAEs) leading to discontinuation and laboratory abnormalities.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;">For more information on this clinical trial, please visit: www.clinicaltrials.gov NCT06054815.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><b style="font-weight:bold;">About DA-1241</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="letter-spacing:0.2pt;">DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and type 2 diabetes (T2D). Agonism of GPR119 in the gut promotes the release of key gut peptides GLP-1, GIP, and PYY. These peptides play </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="letter-spacing:0.2pt;">a further role in glucose metabolism, lipid metabolism and weight loss. DA-1241 has beneficial effects on glucose, lipid profile and liver inflammation, supported by potential efficacy demonstrated during in vivo preclinical studies. The therapeutic potential of DA-1241 has been demonstrated in multiple pre-clinical animal models of MASH and T2D where DA-1241 reduced hepatic steatosis, inflammation, fibrosis, and improved glucose control.</font><font style="letter-spacing:0.2pt;"> </font>Furthermore, in Phase&#160;1a and 1b trials, DA-1241 was well tolerated in both healthy volunteers and those with T2DM.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><b style="font-weight:bold;">About NeuroBo Pharmaceuticals</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. The company is currently developing DA-1726 for the treatment of obesity, and is developing DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists. DA-1241 is a novel G-protein-coupled receptor 119 (GPR119) agonist that promotes the release of key gut peptides GLP-1, GIP, and PYY. In pre-clinical studies, DA-1241 demonstrated a positive effect on liver inflammation, lipid metabolism, weight loss, and glucose metabolism, reducing hepatic steatosis, hepatic inflammation, and liver fibrosis, while also improving glucose control. </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">For more information, please visit </font><font style="font-family:'Calibri','Helvetica','sans-serif';">www.neurobopharma.com</font><font style="font-family:'Calibri','Helvetica','sans-serif';">. </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Forward Looking Statements</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;">Certain statements in this press release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as &#8220;believes&#8221;, &#8220;expects&#8221;, &#8220;anticipates&#8221;, &#8220;may&#8221;, &#8220;will&#8221;, &#8220;should&#8221;, &#8220;seeks&#8221;, &#8220;approximately&#8221;, &#8220;potential&#8221;, &#8220;intends&#8221;, &#8220;projects,&#8221; &#8220;plans&#8221;, &#8220;estimates&#8221; or the negative of these words or other comparable terminology (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including, without limitation, those risks associated with NeuroBo&#8217;s ability to execute on its commercial strategy; the timeline for regulatory submissions; the ability to obtain regulatory approval through the development steps of NeuroBo&#8217;s current and future product candidates; the ability to realize the benefits of the license agreement with Dong-A ST Co. Ltd., including the impact on future financial and operating results of NeuroBo; the cooperation of NeuroBo&#8217;s contract manufacturers, clinical study partners and others involved in the development of NeuroBo&#8217;s current and future product candidates; potential negative interactions between NeuroBo&#8217;s product candidates and any other products with which they are combined for treatment; NeuroBo&#8217;s ability to initiate and complete clinical trials on a timely basis; NeuroBo&#8217;s ability to recruit subjects for its clinical trials; whether NeuroBo receives results from NeuroBo&#8217;s clinical trials that are consistent with the results of pre-clinical and previous clinical trials; impact of costs related to the license agreement, known and unknown, including costs of any litigation or regulatory actions relating to the license agreement; the effects of changes in applicable laws or regulations; the effects of changes to NeuroBo&#8217;s stock price on the terms of the license agreement and any future fundraising; and other risks and uncertainties described in NeuroBo&#39;s filings with the Securities and Exchange Commission, including NeuroBo&#39;s most recent Annual Report on Form 10-K. Forward-looking statements speak only as of the date when made. NeuroBo does not assume any obligation to publicly update or revise any forward-</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;">looking statements, whether as a result of new information, future events or otherwise, except as required by law.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Contacts:</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0.3pt 0pt 0pt;"><font style="font-weight:bold;margin-bottom:8pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><b style="font-weight:bold;">NeuroBo Pharmaceuticals, Inc.</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;">Marshall H. Woodworth</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;">Chief Financial Officer</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0.3pt 0pt 0pt;">+1-857-299-1033</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0.3pt 0pt 0pt;">marshall.woodworth@neurobopharma.com</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0.3pt 0pt 0pt;"><font style="color:#0000ff;margin-bottom:8pt;margin-right:0pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0.3pt 0pt 0pt;"><b style="font-weight:bold;">Rx Communications Group</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0.3pt 0pt 0pt;">Michael Miller</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0.3pt 0pt 0pt;">+1-917-633-6086</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;">mmiller@rxir.com</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>nrbo-20241104x8k001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 nrbo-20241104x8k001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !K 6@# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z**3- "
MT4FX4AD49YQB@!,X[TF:X#QI\=O O@$O'K'B*TBN4R#;0OYLN1V*KDC\<5Y7
MK/[=?@.Q_P"/*TU/46''$0C'YD_TKMI8'%5E^[IMHXIXS#TW:4T?2H(XY'-)
MOQZ5\KVO_!0#PE),%N- U2&,\%PR-^F:[?PY^V1\,?$5PD#:Q+IDCD &_@:-
M23T&X9 ^IK2IEN,IJ\J;_KT"&,H3^&:/=**H:-KVF^(;%+W2[^VU&S?A9[65
M9$)] 02*O;AZUYS5MSL33V%HI,T9Q0,6BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH *:2*3=@>M<K\1_B'IOPU\)7NN:D^(H%PD2GYI9#]U![D_U/:KA"522C%7;
M,JM6%"#J5'9(K_$KXI:#\*M".I:W=>4&RL-N@S+,P[(O?KR>U?"WQ:_:I\7_
M !&FN+6SNI- T1C@6MHV)'7_ &Y!R?H,#GO7$_$KXAZO\3_%%SK6L3&21SMA
MA!^2"/G:BCL.?Q//6N/<9Z<U^E9;DM+#14ZRO/\ !'Y)F'$57&5'3H/EIK[W
MZE9\L<G)SSGOGO4#KQ^E>X?!7]F+6_C+ID^JQWL&E:7'(8EEF4LTK#&[:H[#
M(YK(^(/[/U]\+M=:T\2:M96EFR[X+J/+-<+_ +*=0?K7KQQV&]J\/%KF71%T
ML-B/9*O)/E?4\@8<9[5I:/X0U;Q$V;&QDFC[S$;8U'NYXP*Z)M;\->'F_P")
M7I3:K=(.+K4C\F?41#@CV.:Q-?\ &FL^(5$=W>.+=1M6VA_=Q*/3:,"NI.<_
MA5O7_(].E)1U;/TK_9OM]"L/A%H%IH<MI(;:!8[PVCA_]*P#+N(ZL6)//8CV
MJ_KOQW\'>&_B!9>#M1U:.VU6ZC#J6(\M&)PJ.W\+-VS_ %%?(_[ SO'X[\5,
M)&1%T<D@,0/]:F"1ZCG\S7S"$GU740-S3W5S)C<YRS.QZY/.237P<,EC7Q=:
M,Y[:_>?8+&VI0:6_Z'[-!\G&>:4'/6OF']GG]H*UF\4CX9ZO=&2ZL88X-/OY
MG)-RR(-\;9_BZD$]<'VS].AL=J^6Q.'GA9NG4/6IU%4C=#Z3-&:Y;XE?$/3O
MA=X,O_$NJI*]C9>7YBP %SOD5!@?5A6$(NI)0BKMA.<:<'.;LEN=517 ?"3X
MU^'/C/HDVI>'YW802>7/;S ++$>HW+GH1T/L?0UWH?-55ISHS<*BLT*E5A6@
MJE-W3'4F:,URWQ+^(>G?"WP9J'B75DE>QLO+\Q85!<[Y%C7 ^K"IA%U)*$=6
MRISC3@YS=DMSJJ*YGX>^/;#XD^#].\1Z8DJV-\A>)9AAP Q7D?5372;J)Q<)
M.$E9H(3C4BIP=TQU%)FC/-26+130^3THW>U*X#J*3-&:8"T4TOBC>*5P'44W
M?[4;O:F ZBFE\=J3S,=1@4"N/HI-U)NH&.HIH?/0<>M>)?%']K;P?\)?%TWA
MW5[?4)+Z*-)6-O"&3##(P<^E=%"A5Q,N2C&[.7$8JCA8<]:7*O,]NS1FOF3_
M (> ?#S_ )]-6_\  <?_ !52P?M]_#>20+)%JT.>[6V1_.N]Y3CE_P NF<"S
MC /_ )>H^EZ*X;X=_&KP?\4[5I?#FL0WLJ#,EL3MFC'J4/..1R,CFNX#9KS*
ME.=*3A45GV9ZE.K3K1YZ<DUY"T4W?[4NZLS46BF[J-] #J*** (V&!7PI^V3
M\0I/$GCQ/#EO*?[/T9?G /RO.R@L?P4A?8[O4U]SSRB.WD<]%4DG\*_-GQ)\
M1X9=>U+4=)TN"&\N[E[B2]NAYTI9F)RN>%Z]J^GR"A[2NZJ5^7]3\XXTQRH8
M:%#FMSO[TNARUAX#U;4(?M#PK8V@ZW%XPB7\,]:F>R\*Z"&^TW,VOW(./+M\
MQ0YQS\QY/3M65J^L7^M7#37UW-=2$Y_>N2![ = /85WW[/WPMB^(/B\W>J 1
M>&M'7[9J$T@PA5?F$9]FP<C^Z#[5]]7G["FZE65DNB/S3+[5ZT:=&.O=GOO@
M+XJ1_ CX%V&JZ]ID=L-3N6?2=&LAM<0D*2S,3S_>R?[R^M>??M1))\8O!_A_
MXF:#,UWHUO#]DO+/ ,EE(7R2V/4D YX^Z>AKROX[_$^7XJ^.KB_C+1Z5:C[+
MI\/0)"O0X[%CR?P':KWP!^+Z_#7Q!<:?JR?:_"6M+]FU.T<;E (($@'L&(8#
MJ#W(&/ AE\Z$5CH+]YJVO)]/6Q^@K,X5I_4F_P!VK)/S77TN>.NO&.F#BH6%
M>L_'SX/-\+/$Z/8,;OPQJ2FXTR]0[E*-SY9;N0/S'->4NM?3X>O#$TU4CLS&
MTJ,W"6Z/H_\ 8DD^RZWX\N,X\K09&S_P(&O$OA=817'BR.\N5WVNFPO?R#_<
M&5_\>(/X5[)^R*QAL/BG../+\-S?R8_TKR73 =!^%^KWF?+GU>Y2SB/\1C0;
MG(]B>*\:E_O>(2Z\J_ ^EB[T:?S_ #.53Q#?V_B)=<M[A[;4DN?M<<\3$,DF
M[<"/3FOU?^#_ (]A^)_PYT/Q+$ CWL ,R#^"5<K(/P8&OR0/O7WE_P $]/$,
MU[X \2:-(Q>*PU!9HMQ^ZLJ<J/;,9/U8UQ<1892P\:RWC^3/3P%1\_*SZR'6
MO$?VS 1^SAXN .!BU_\ 2J&O;AUKQ+]LSC]F_P 7?2U_]*HJ^'R[_?:*_O1_
M-'5FG^XUO\+_ "9\A?#K2O%7P,\'^$?B_P"'#)?Z/?K+;ZS8A<KL6=T&[CA6
M"*0W9AZ'%??WP[^(VC_$SPM9:]HEPL]I<KRN?FB<#YHV'9AZ?CT->9?LD:59
M:Y^S!X9L+^UBO+.XCNXIK>= Z2*;F8$,#P1]:\3N+?6OV)/BCY\(GU'X9:[,
M%9&^8VY'(Y[2(,X_OJO/(&/I,<XYI7JTGI6@Y6?\R3V]5T/ELOY\HH4JL=:,
MTK_W6TM?1GW*.M>'_MG9'[-WBWGC_1/_ $JAKUW0/$%GXFTBSU339TNK"[B6
M:&>/D.A'!KR+]LX_\8W>+1_UZ_\ I5#7SF7IK&THO^9?FCZC,9*> JRB]XO\
MBU^R*/\ C'CP?_UPE_\ 1TE>Q%@,'M7CW[(V1^SSX/Q_SPE_]'25R?[47Q^U
M3P3=Z9X(\&!;CQGK!"*R@.;5'.%.#_$QSC/0 D\5TUL-4Q>8U*5/?FE^>YRT
M,73P>6TJM3;E7WGM_B+Q[X<\)E5UG7-/TMG&56[N4C9AZ@$YIOA_XA>&O%,C
M1:/KNG:G*H),=I=)(P&>I .<<BOG;P+^P_HUW8+JGQ#U/4?$GB.Z DN";M@B
M,<$C?G>Y!S\Q/X4OCO\ 8;\/P6!U#P!J-_X:\06W[RW873,CM@D+N^\AZ?,#
MVZ5JL-E]_9NL^;:]O=_SL9?7,RY?:>Q7+:]KZGU0' Z<U1U;7]/T*!9]2OK?
M3X&;8);F58U+$$@9) S@$X]J^?/V4OCMK/C:75/!/C.)XO&&B AY)% ::-6"
M-NQQO5B,D<'<".]9?_!0T[?@]H0!(QKL7/\ V[W%<L<OFL9'"3=FW:ZUT[G3
M+,X/ RQE-;+9]'V/J.*X2XC26-@Z,-RLIR&!Z$&I3WKG?A\,^!?#Q/\ T#[?
M_P!%K71XKS9QY9.*Z'KTI\\%+N96L>)-)T)HEU+4K33VESY?VJ=8]^,9QDC.
M,C\ZTLCI7Q3_ ,%&^+SX<\_\_P#_ #MJ^THN;=2>?EKNKX3V6&HXCFOSWT[6
M=OQ/.P^-]MBJV'Y;<EM>]U<I6WB#2[O49=.M]0M9[^ $RVT4RM)'R =R@Y&,
MCKZT_4]:L=$M&N=1O;>PMDX::YE6-!]6)Q7P*WQ=@^#/[37Q2UR2W>_NY%FM
MK*T!.)9VDB(&><# .<>F*[W0_P!ECQG\;[J+Q1\5O$UU:FXVR1Z1:X'D1D<(
M ?DCXQT!.1R222?3GE$*"C4Q%3E@TFN[;W27D>13SJIB'*EAZ7---KR5MFWY
MGUSH_B/3/$EE]KTJ_MM2M-Q7S[659$W#J,@XS4VH:G::9:27-Y<PVEM&-SS3
MR!$4>Y/ KQJZ3PI^QU\'[][22[N[-)VE@AO)5:6>X< ! 54  [<GC@ UXKX(
M^#?C/]JR6/QC\0]9O-,\,SMYEAI-J2H:,YP44\*"/XR"6Z],5RTL!3J*5:4^
M6DGHVM7Y)=SLJYC4IN-",.:J]TGHO5GU0GQF\"-<"!?%^BF0G&W[='U_.NMM
MKV&]MXYK>5)XI!N5XV#*RD9!!'4&OG^?]A/X62VC1I9:C#*00)DOF+@GN,Y&
M?PKQ_P 2^&/'O[%VJV^N^']5G\1> Y9A'<V-SDB($\*P_@)Z!UQSU':MH8'!
MXI\F%JOGZ*2M?T9C/,,;A;3Q=)<G5Q=['W-GC KXN\9VL-Y_P4#T*&XB2:)K
M= R.H96_T:3J#7U?X"\<:?\ $3PAIOB+2F,EE?1>8F>&4YPRD>H((/N*^1_B
M%K5CX?\ V]]&U'4[J*QLH;=#)<3N%1/]%D R3[FMLFISC6KPM[RA+UOH8YW5
MIU*-"HI>ZYQ?R/L@>%]'/_,+L_\ OPO^%4]0^'_AK583%>:!IMU%TV3VD;C\
MB*QA\<OA_C_D;]&_\#$_QJKJ/[07P[TRTDN)_&&DB.,9;9<J[?@JY)_*O(5+
M&7TC+\3UW6P%M91_ ^4_VH?A5!^SKXF\/_$7P"QT19+XPRV43L(EEP7 5<\1
MLJN"G3ICCBOMCPQK2^(/#FF:FBE%O;:.X"'JNY0P'ZU\8?%#Q1J7[9OC;1O"
M_A"TN8?!VF7/FWNJS1;49\8+#/=49@J]26/:OMG2M+@T?3+6QMT"6]M$L,:#
MLJ@ #\@*];,Y36'HT\1_%5[]TNESQ\H4'BJ]3"_PM+=K];%CS1@9Y/H*P=?^
M(7AOPM)Y>L:]INF2D!@EU=)&V#WP3G'!KYW_ &C/CYXBN_&T'PN^&Q9O$=R1
M'>7T9^:WW+DJI_A(4[B_\(Z8/1_@[]A3PRMI]K\;ZIJ/B36YSYD\HN&C0,>3
M@_?8YSR3SGI7-#+Z5*G&KC9\JELDKMKOY([:F8UJM65'!4^9QW;T2/H/0/B+
MX9\4S&'2=?TS4IP"?*M;I)'P.^ <UT!DP> .:^7?&7["'A:>T^T>#M1U'PYK
M,)WP2F=I(]PSC.?F4YQR#QZ&J7[/?QV\3>'?'LGPJ^)A<ZU$?)L=1E/S38&5
M1F_CW*/E?J>AR>:)Y?1JTY5<%/FY5=IJSMW7<F&95J-6-+'4^7FT36JOV/K:
MBF[N,T5XA]'N5+[/V.8 ;B4;CUXK\TKJ;PQJTDJW%I<:'<Y.7MV\V+.>?E/(
M[]*_3(KYD97')'>OS6^,7A)_!7Q(U_2MFR*.Y:2$#_GD_P R8_X"P'X5]AP[
M)>TG!NS/R+C]5*=.A7BKQ3:=_,H1_#6]UB=(]!N;?6VD8*D=N^)3DXY0\CK7
MJ?QDOH/@M\,M/^&.D/\ \36^1;W7+R+Y2V>B?0D ?[J@?Q&CX%Z'9?#KPKJ?
MQ2U^)2+96@T>V=MIFF.02!^:C_@1["O+;[XK:WJ]_=3ZRMMK27$K2O%>PJV-
MS$D*>H Z#T '%?0VGC,1RK6$/Q?_  #Y/#2HY=@U-^[4JKUM'_@_D>?NM0/S
M7<,GA+6@.+KP_/GU,\)_/YA]<U3N_AUJ#1//ILD&L6Z8)>R<,P![E3R/\\5[
MJJK9JS\R:"EO'5>1ZQ\#O&>F?$OP?/\ "+QA*HCN,MH6HR ,]K/U6,$^_3GD
M,R="*\)\;^#=1\!^)[[0M5A,5[:2;2.S@C*N#W4C!'UJI*ESIEV 1+:W,1!P
M0492.A[$&OI6\C@_:P^%XN$\M?B;X;AQ(@ 4ZA;X'('?GIZ-D<;A7CS?]GUO
M:Q_ASW[)]_1]3[;#5?KE)4Y?'%:>?D<]^RHFWP;\9)AU3PW(/SCF_P *\D^)
M(73(="T!3SIUF&F]II#N?\!Q^=>[_L<VB+X:^+L5W%M4:7'%+'(.F5N 5(_#
MO7S5XJU9]?\ $.HZ@W/GS,RCT7HH_ 8J<,N;'UGTT_(]KFY<-3]'^9AL*^V/
M^"=,#+8>.)<G8TMH@^H64_U_E7Q4PK]%_P!B'P2WA/X+P:A,FRXUNY>]^9<,
M(AA(Q[C"%A_OUGQ%54,'ROK8]++O>JW1]$BO$OVS?^3</%W^[:_^E45>U.>,
M\BO$_P!LSG]G#Q=]+7_TJAK\^R[_ 'VB_P"]'\T>IFG^Y5E_=?Y!^QIG_AG#
MPEQVNO\ TJFKTGQWX(TGXB>%[_0=;MA=V%W'M<'[RGJ&4]F4X(/J*\W_ &-!
MC]G#PC]+K_TJFKVI0",]CVJL=)PQU647:TG^;,\OIQJ8"E3FKIQ7Y(^)_AAX
MSUK]D;XCGX?^,9GG\&:E,9=-U-P=L18@;@>R]-Z_PD@]R3[1^V1<)<?LU^*G
MC99(Y!:,K*<@@W4/(KK?C9\'M)^-7@Z;1-3'ES(WG6=XHRUO*. P (R,'!!X
M(/J 1\2>*_B9XB\#_"3QA\&?'$<O]HVBP?V5=-\V^);F-MF[NNU24/H"O& *
M^APD8YG7I8FFK58RCS+OJO>7ZGS>,G/*J%7"U&W2DGROMY?Y'U[^R03_ ,,[
M>#^,_P"CR_\ HZ2OE1OBB=(_;'\5^)[GP]J/B!],FN+."RTR+S9(_+ @#X/1
M=H8G'=AZU]5_LC'_ (QX\'CI^XE_]'25X+\4;E_V>OVN[+QM=0,OAGQ"FR>2
M(85<HJ29 ZD.$D([YSUJL&X_7L73:NY*:2O:^NWS%CH3>!PE1.RBXW=KVT/0
M_P#ALF8_\TK\8$_]>1_PI1^V7.!C_A5?C ?]N1KZ*TK4K+6;"&]L9XKNSG02
M131$,K@]""*MN$5"6"@#N17@.MA5+6AK_B9] L/BW&ZQ.G^%'P1X3U?5?$G[
M7^C>--*\':[H=AJ,P2]COK-T0%H3"S$@8P0%;G^($FO4O^"AY_XL_HO_ &'8
M?_2>XKW70_BQX2\1>,[_ ,+:?K%M<ZY9(&FMHSG'7< >A*\9 Z9Y]O'?V]O#
MUUK7P12[MU#1Z9J<%W..X39)%D?1I5->I3Q3Q&/PZE#DY;)7[=#R*F#CA<NQ
M#A/GYFY-_F>[?#S_ )$/P]_V#[?_ -%K71=Z\P_9Y\;VOCGX.>&+^UN5N)X[
M*&UN@I&4GC15D4CMR,_0BO2B^WJ<#WKYW$0E3K2A):IL^HPE6%3#PG%Z-(^*
M_P#@HY_Q]_#G_M__ )VU?:</_'NG^[7Y]?MX?$G3O&'Q$T30-.E2Y_X1]94N
M)D.0)I63=']5$2_0DCM7Z"0G,"=OEKW\QI3I9=A(S5OB?WM,^>RRK"KF.+E!
MW7N_@CX2\!^";;QG^W5XD:\436VDW<^H^61\K.A58\_1F5O^ BON\*#@X_"O
MCWX%#=^VS\2_:"X/_D6&OL3D-7/G-24ZE*/:$?R-LBIQC2JR76<OS/B[]NJ:
M;Q1\1/AOX-,S6UE=S%I&W?+NEE2(,1ZJ W_?9]:^Q]+TZWTK3;6SMHEAM[>)
M88HU'"HH  'L !7S#^WC\-K[Q%X.TGQ?I2R->^'I7,PB'S"!]IW\<_(R*?8,
MQKUSX$?&?2OC'X(L]1M;A!J<2+'?V>0'AEQ@\?W202#Z?2M<7%U<LH3I:J',
MGY-N_P"*,\).-'-*\*NCFDUYJVWR9Z9M&[.:Y7XG>'+/Q9\/O$&D7\8EMKJQ
MFC;</N_(<,/<$ @]B*ZD'_)KPS]JOXW6'PM^'FHV$%VC>)-4@>WL[92"Z!P5
M,I'8*,X)ZD8YYKQL'2J5:\(TEK?^G\CV\?6IT<-.55Z6_I' ?\$[]3GN/AQX
MCL)'9H+75-\2L<A-\2[@/097./4D]2:X;XQ>#-+^(?[;VG^']9C>;3;VVC6=
M(W*,<6\CC!'(Y4?E7N'[&GPMO/AK\)(9-2C>'4M8F-_+!(NUHE("HA'KM7<?
M0L1VKRSQ2-O_  4)T$?].Z_^DLE?7T:REF6*JT']F6J\DDW^I\;6I..682E7
M6\HZ/S>AZ7_PPM\*O^@;??\ @=)_C44_["?PNFA9([/48&(X=+Y\K[C.1^8K
MZ)W*.X_.C>OJ/SKYC^T\:GI5E][/JO[*P#6M-'Q9XV^!?C3]F&PN?%WPV\47
MEWHUD?-O-'OOG7R^,L4&%<#N0%8#[IKZ/^"WQ<M_C#\.;/Q+;0FUD8/%<VQ.
M?*F7[RY[CH1[$5SG[4'Q1T7P)\*=>MKZZB.HZG92V=I9@@R.TBE-V/[JYR3[
M5SO[#OA.^\,_ U)KZ)X3JM[+>Q1R#!$95$4X]#Y>X>H(->G7G+$X%8G$KWU*
MR>SDOUMW/(H0CALP>%PK]QQNU?9_I<\R_85M1XO^)7Q%\9:F?/UCS%0.>@\^
M21W./K&H'H,CO7VJ%!ZCFOA7P'JG_#*/[36N:+K.^S\(Z^Q-O<-_JPA8M"Y/
MHFYHV/N3TK[BM;N*[MX[B&9989%#+(AR&!&001V/6LL\BYUU6CK"2CR^EE^1
MOD$XPP\J$M)Q;YE\]_N+ 4#'K7Q=^WWIL7A[Q/X \76*_9]925XC<)PQ$3))
M&?\ @+%^?>OLJ>X2TC:65Q'&@)9W.  !G)/M7Q#\5=;;]JO]HOP]X5T%S=^%
M]!<M=7D2_+C>IG?=Z$(J+ZG)'6C(XN.)]M+2$4[ORM;\6//IQEAO81UG)JR\
M[[_(^X+*4S6D3GJR!L?A14\48CC50  !@8HKP9.[T/I8+EBDQH)S[$<5YK\1
M/@%X8^)VLVNIZS'<_:8(3"?L\FP.N21NXR2"3CGN:]/HJJ52=&7-!V9AB<+0
MQD/9UXJ4>S/C[]JWP)JZMX9TK3&MK?PQ9VQCMK5Y0A61< D[N2=NW!^OJ:^>
MI?AIK7\(M6^ERAKZ?_; ^'OBOQ(VGZS8 ZAHUA$P-G;I^\A9OON<<N#A?IMZ
M<DGX]D+ _>(.<>G-?I>33E4PL>62TW_X)_/?$L(X;-)\]-J+M9WZ6Z>1MO\
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>nrbo-20241104xex99d1001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 nrbo-20241104xex99d1001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !S 5<# 2(  A$! Q$!_\0
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M^#KJG4BX+[S[K_:'_:PTKX/WMOI.DK%K'B)9T-W9G(6&'J=S=F(Z=?4UZO\
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MS'9:/JEOXYU":2]@*"32K>YMS$ZD_P#+1U/?T_.NFECIX# 1EBU::6B[]O\
M@GI>PCBL7)89WC?[NY[M\"OANGPK^&>D:%M NUC\ZZ8=YFY;\N!^%>@445^:
M5:DJTW4GNW<^TA%0BHK9'GOQ_P##&I^,OA%XET;1[8WFHW=J8X8 P7>V>F20
M*S?V9/!NL> O@[HVBZ[9FQU* OYD!=7VY;(Y4D5ZI172L9-85X2RY>;F\[VL
M<;P5-XM8R[YN7E\K7O\ >%%%%<)WGQ_^U;^R;J'C#Q'!XK\$:>EQ?W$@&H6*
M.L>\]I5W$#/J*^K/"UG-I_AK2[6X3RYX;6*-TSG#!0"*U**]3$YC7Q>'I8>J
M[JG>SZZ]'Z=#RL-EF'PF(JXFBK.I:ZZ:=5Z]3P#]HK]F$?%*\M_$_AF^&A>,
M[/!CN0Q1)]OW0Q'*L.S?G7G.G?%C]I;P-#_9>J^ $\3R1#8E\MNTA<#N6B;:
M?R!K[%I,5UT,WG"BJ&(IQJQCMS7NO)--.WD<E?)X3K2Q&'JRI2EORM6?FTTU
M?S/B^\^'GQY_:4N8K7QJ\?@GPGO#2V<0$;. >GEABS'_ 'S@>E?5OP^\ Z1\
M,_"ECX?T2$PV-JN!O;<SL>K,?4GFNCQ2USXS,ZN,@J*BH4UM&*LK]WW?J=&"
MRNE@YRK.3G4>\I.[MV79>2/G[]I?]FVY^*=Q8^)_"UZNE>,M-QY4A8HLX4Y4
M%A]U@>AZ=C7GNE_&7]I'PK;#2]3^&RZ]=1#8M\+=SO[99HWVGZ\5]ATF*Z*&
M;RA1CA\12C5C';FO=>2::=O(YZ^3QG7EB,/5E2E+XN6UGYM--7\SXY_X4;\4
M_CW/<:]\4Y%L+*TMI7TWPW:N$#3%#LW $A1G&2Q+'V%>G_L=_#?Q#\,?AO?:
M7XDTXZ9>R:A),D1D1\H54 Y4D=C7O%)TI8G.:^)H2PSC&,':R2LE;MZWUO=L
M,+DM#"UXXI2E*HD[MN[=[;Z=+:6LD?-_[5OPI\4_$7Q9\/;SP_I;:A;Z7>^;
M=N)43RE\R,Y^8C/"GIZ5]'0J5B0'@@ &G8I:\^MBYUZ%*A)*U.]OF[ZGHT<'
M3H5ZN(BW>I:_;16T$(S7R=\5_P!E+Q'X=\:OX[^#^I#2-69FDFTO>(U8GEO+
M)^4JQZQMQZ'M7UE15X+'UL!-SHO1Z-/5-=FB,=E]#,(*%9.ZU33LT^Z9\?0?
M'3]I"PMOL%S\+8KN_ VB\%G)M)]3MDV'\"!47AS]FOXA_'#Q9:>)?C/J7D:=
M;G=#H5NZY(SG9A/EC4\9.2Q]NM?8N*6O4_MMTTWA:$*<G]I)W^5V[?(\K^PU
M5:6+KSJQ7V6U;YV2O\R"RLH-.LX+6UA2WMH$6.**-=JHH& H'8 "OC[XW?##
MXL0?M(R^/? >A)>"&VBC@N99(2A/D^6X*.P/<U]D4F >U>=@,PG@*LJL8J7,
MG%J6J:>_5'I9AE]/,*4:4I./*U)..C36W1GQU_PD_P"UG_T+^G_]^[7_ ..4
MC:G^UKK"FV73[#3-XP;@+:*5_$LW\J^QL#T%&!Z5Z7]M16V$I?\ @+_S/,_L
M.3WQ=7_P)?Y'RK\+OV/-3N/%\7C+XJZ]_P )/K*,LD=D':6(,.5\QVQN [(H
M"_7I7U4  ,=J6BO)QN/KX^:G7>VB2T279(]?!9?A\O@X4%OJV]6WW;/F3X\?
MLI7^O>*5\=_#C4AH'BZ-_-DB#F)+AQ_&K#[KGH<\-WQS7+V/QI_:4\-V_P#9
MVI?#6/6KM!L%ZMJYW>Y,3[#^&*^PZ3%>C2SF?LHT<52C54=N:]TNUTT['FU<
MEA[65;"U94G+=1:LWWLTU?S/C&#X%_%[]HS7;2^^*E\/#OARW?S$TFW*AC[+
M&I(4GIN<DCL*^O/#?AS3O".AV6CZ3;)9Z?9QB*&%!PH'\SW)[FM.BN/&YE6Q
MJC"2481VC%62_P"#YL[<#EE' N4XMRG+>4G=O_@>2"BBBO*/6"BBB@#R7XU?
ML[Z)\7(#>*1I?B"--L=_&F1(!T65?XA[]1^E?$GQ&^#/BOX9W3IK.ER+:@X2
M^@!DMW^CCI]#@U^FM1S01W,3Q2QK+&XPR.H(8>A!ZU]!@,YKX)*#]Z'9]/1G
MPV<\)8+-9NO#]W5?5;/U77UT?J?D?(M/TW2+O6K^*SLH6GN)#A47^9]![U^D
MGB;]FWX=>*I'ENO#5M;SN<F6Q+6YS]$('Z5CZ?\ LH>!M)LKJVL?[2M/M/$D
MT5T/-*_W0Q7('TKZ=<289Q^%I_UYGR%/@S'49V<XN/DW?\4?#E_J5G\/;273
M](D2ZUV1=EUJ2\K!ZQQ>_J:YCPSX*U_QYJ@LM#TRZU:\D/(@0MC/=FZ#ZDU^
MA>B?LC_#+191*=";47'>_N7D'_?.0#^5>JZ-H&F^';);32["VTZU7I#:Q+&G
MY 5RU.(J5.+]A!RD^KT_*_W:'TF&X;Q$FOK$U&*Z1U_.WWZGS)\!_P!BZT\+
M7%OKGC<PZEJ28>'3(SN@A;L7/\9'IT^M?5*J$4*H"J!@ =!2T5\=BL96QD_:
M5G=_@O0^YPV%I82'LZ2LOS"BBBN,ZS"\<^+(O _A34]=GMY+N*QB,K0PD!W]
M@3Q^=<58_&Z>VN]+7Q+X/U;PQ8ZFZ16VHSRP3P%W'R*YB<E,]B1BK_[0.[_A
M3OBG8 7^R' /3.1BN8M/!7CCXAZ7X>M/$TVA:7X=M3;W;PZ4\T]Q<E "BEG5
M0@SC. 37MX6C0>']I62W:;N[I)+9+=Z]G\CP\56Q"Q'LZ+>B32LK-MO=O9:=
M&OF>C^./&MOX&TNUO;FWEN4GNXK0+$0"&D;:#SV%)XU\;V_@FWTV6XMY;@7U
M[%8H(B 59S@,<]A7%?M*03W'@2PBM;G[)</J]F([CRP_EMYG#;3P<>AKDOBG
MX7\6Z2?"D^L^-FUZS_MVU'V0Z3#;\[C@[T.>*>%PE&M"G*<DFW+36[M:UK*W
MWM"Q6,K49U8PBVDHZZ65V[WNT_N3/H7/%<%IGQCTC5/BE?\ @>."=;VUA\S[
M6P'DR..6C4_WE!!/UKI/&/B2#PAX5U/6;@CRK*!I2#W(' _$X%?+^[Q7X<\&
M:'XBG\":K;:EIVI'6[S5I+JV9'CE/[T% Y<C81QC(Q4X#!QQ,9.?72.J7O?/
M>VBMYCS#&SPTX1I]/>EHW[NUM-KZM-]CZWED$43N1D*"W'M7D.G_ !\U/4=&
M?7(?AWKL^@(SEKZWN+:1@B$AG$7F!R!@G &:]1AU"'5=#2]MW$D%Q;^;&P/5
M2N17RUH>L^/_  _\%+:XMKO1[;PE+<2P7=U!9RRWUG;O(RM+AGV-C/)QQG/.
M*K 8:%:,N=)OFBM6UO>]K==-!9ABIT91Y)-+ED]$GMRVO?IKJ?4NA:[9>)=&
ML]5T^83V5W$LT,@&-RGIQ7*?#+XOZ/\ %"36H+!9;:\TB[:UN+><C=P<!QCJ
MI]:WO!.B:?X<\(:3INE2F?3K>W1()2VXR+CAL]\]:^=?"GPTUWQ#X476?"%]
M%I6M2:E?:;?S/TDLGG;<1_MIR5/O48?#8>JJO-+ELTHM]-]_DOO*Q&)Q-)T>
M6/-=-R2ZVMMZ-_<>V> /B_H_Q(\0^)=+TA)9%T.<6\ET2/+F8CG9WP.F:Z7Q
M5XDM/"'AS4=9OB1:V4+3.%ZM@<*/<G 'N:\J^#/AVS\)?%'QYH^GQ"*TLX;"
M)% ZXA&2?<GD_6G_ +0&KWNIZGX9\(Z7I-QKTMS<C4K^QM)(XW:UA((!9R%P
MTFWJ>=IJIX2E/&1I4M(63U?3E3>NQ,,76A@I5:NLTY+1=>9I:;L] ^&WC^R^
M)?A&SUVR@FM$GW+):W Q+"ZG#(P[$$4[Q[X_T[X?:5#=WL=Q=W%S,+:SL+*/
MS+BZF/1$7(^I)( ')->8?"C7=1T/XM>(M&U3P[=^&+37T_M:QMKR>&7,J@+.
M%,;,.3M;&<\FM7XMW46@?%/X<:[J;"+1(9;JS>YD.([>>5%$;,>@W;64$^M$
ML'!8SV=O=:<DD[WT;M=;ZKE".-F\'[2_O)J+;5K:I<UG:VCYM3IO"WQ!US5M
M;CTW6O NK^'O.C,L-V\L-S 0.JN\;'8W/0CGUI?B%\2YO!6L:#I-EX?N_$.I
M:P9O(@M9HHMHB52Q+2,!T85U4FN:=#?VMB]_;)>W2EX+<S*))5'4JN<D#/45
MY'\:K#4=2^*WPS@TK5_[#O6_M$K>_9TGV 1QY&Q^#FLL-"E7Q"YX*,;2=O>M
MI%N_5VNM;,VQ,ZN'PSY)N4N:*O[M]9)6Z1O9Z71Z%X.\4:[X@FN4U?PC>>&D
MC53&]U=P3"4G.0/*9L8]_6I+CQQ;VWQ"L_"9MI3=7.G2:BMP"/+"I(J%3WSE
MLTG@K1]=TB*Z77/% \2N[ Q-]ABM?*&.1B,\Y]ZXOQ'<1:7^TEX5GNY%MX;W
M0+NSMY)#A9)A-&YC!_O;<G'L:B%*G5K3BDK*+:M>UTK_ &M?O*G5J4:,)-N[
MDD^;EO9NWV=/N_,[2X\<VUO\0[/PD;:4W5SITNI+< CRPB2*A4]\DL#^%97Q
M.^(^I?#FQN-1B\)WVNZ3:6CW=W>6MS!&(%3)8%78,QP,\ US\TT>H_M/V8MI
M%G.G^&)EN_+.?):2Y0QJWH6",0/09K?^//\ R17QU_V!;O\ ]%-6D*-.%>A"
M4;J25T[]7Y-=+&<ZU6="O.,K.+=FK=$NZ?6]R]\/_&>K>,K5KJ_\*WGAVV>*
M.:WDNKF&7SU<9X$;$C QUQUJVWC6W7XA1^$OL\OVI]+;5!<9'E[%E6/;ZYRV
M?2I_ W_(E:!_V#[?_P!%K7$R_P#)S=M_V*$O_I9'62ITZE6JN6R2=DK]/5MF
MSJ5*5*D^:[;5V[=?1)'7^//'FF?#S0CJ>I^=('E2WM[6UC,D]S,YPD4:#[S$
M]OJ3P*Q/#/Q%U[4]<M;#6? .LZ!%=JS0WCRP7,*X&=LIC8F,D=,\9XS7/?'&
MXBT+Q?\ #3Q#J1":!IVL.EY,_P#J[=Y8'CAE<] H<XW'IN%>H2Z[IMO=65M+
M?VL=S>Y%M$TRAY\#<=@SEN!GBJ=.%/#PER<SFGKKI9M65M--W>^C6Q*J3J8B
M<>?E4&M--;I.[OKKLK6U3W+KN$4LQP ,DUPOPO\ C!I/Q4EUR/3H)[9M+NC!
M_I  \^/)"3)ZHQ5L'VJI\??$][X>^'5W;Z1$]QKVL.NEZ=!$0'>:7Y<@D@ J
MNYLGCBO,=$O=1^'GQ#\$7<O@S4?"NA26:>&;J>\NK>5'Z&V8B)V((<,"3_ST
M-;87!1K8:4W\3ORZI?#J]-W?96ZF&*QTJ.)A"/PJW-HW\6BUV5MW?H>\>./%
MD'@;PEJNOW,$ES!I\#7#Q1$!F"C.!GBM33;U=2T^UNT4HL\22A6Z@, <'\ZX
M3]H3GX*^,?\ L&R_^@UUOA69#X;TA0ZD_9(> 1_<%<+I1^K1J+=R:^22_P S
MOC5D\5*ET44_FV_\C"\=?$C_ (135--T;3M&N_$6OZBKR0:?:.D>(TQOD>1R
M%51D#U)(XK0\%>*K[Q1:7+:CX=U'PW>6\GEO;W^Q@_&=T<B,5=?<5SWQ%\(Z
M1XM\1:4+?Q+)X:\:6<4DNGW-G,GGF(X#AHGR)(SQD$?B*C^$WC36]8U;Q+X<
MU^>RU+4-!FBC.J:<ACBN5=21N3)V2#'*@XY%=3HTY87GA'WDKN][[VNOLM;+
MO?R.55JD<7R5)>ZW:-K6VO9_:4MWVMYGI-%%%>2>N%%%% !1110 4444 %%%
M% !1110 4444 4]7TBRU[3I[#4+:.\LYUV2P2KE7'H15B"%+:&.*)0D<:A55
M>@ & *DHIW=N6^@N57YK:E#6-"T_Q!;QP:C:17D,<JS(DRY"NIRK?4&C5]!T
M_7DMTU"SBO%MYEGB$JYV2+]UA[BK]%4IR5K/8EPB[W6Y0UK0M/\ $5@UEJ=I
M%>VC,KF&9=RD@Y!Q[&K%S8V]Y9RVD\*2VTJ&-XG7*LI&""/3%3T4N:5DK[#Y
M8W;MN4]-TBST?3(-.LK:.VL8$\N.",85%] /2J]CX8TG3=%;2+73[>'3&5E:
MT5!Y9#9W CWR:U**?/+77S^8N2.FFVGR*6C:+8^'M,M].TZVCL[&W79%!$,*
MB^@'84W1M"T_P]:-:Z;:165NTC2F.%=H+L<LWU)YJ_10YR=[O?<%"*M9;;&?
M::!IUAJE[J5O9Q0W][M^TW"+AY=HPNX]\#BA- TZ/6I=76SB&IR1"![K;^\,
M8)(7/IDFM"BCGEW\OD')'MY_/N9]_P"']-U/4;"_NK*&>]L&9K6=UR\)88;:
M>V1UJ35]'L=?TZ?3]2LX+^QG79+;W,8>-QZ%3P:N44<\M-=MO(.2.NF^_F<E
MX2^$W@_P)=R7>@^';#3;J1=C3Q19DV_W0QR0/8<5:\8?#KPUX_6U7Q%HMIJX
MM2S0?:4W>66QG'IG KHZ*U>(K.?M7-\W>[O]YDL/15/V2@N7M96^[8Y?PC\,
M/"O@.XN)_#^AVFDS7"A)7MD(+@'(!Y]ZO^*O!VB>-],_L_7M+MM5L]P<17,8
M8*PZ,IZJ?<<ULT5+K593]JY/F[WU^\:H4HT_9*"Y>UE;[C!\(^ _#_@*REM?
M#^D6NE0ROYDHMTP9&]68\L?J:T]6TJSUW3+K3M0MX[NQNHFAG@E&4D1AAE([
M@BK=%3*I.4^>3;??J7&G"$/9QBE'MT^XBM;6*QMH;>"-8H(4$<<:C 50, #Z
M"JIT+3SKBZR;2+^U%MS:"[V_O!"6#%,^FX X]15^BI4FKM/<IQB[)K8K:CIM
MIJ]C/97UM%>6DZE)8)T#HZGJ"IX(KF/"GP@\%^!]0:^T+PWI^FWI4H)XHLNJ
MGJJDYVCV&!7845<:U2$7",FD]U?1^IG*C3G)3E%-K9VU7H9]_H&G:I?V%[=V
M<5Q=6#M):RR+DPL5*EE]#@D9]Z-<\/Z;XET]K'5+*&_M&97,,Z[EW*P93]00
M"/I6A14J<DTT]MO+T+<(M--;[^?J4M9T:Q\0Z7<Z;J5K'>V%S&8IK>9<I(IZ
M@CTKD]"^!_@/PSJEMJ6E>%M/L;ZV;=#/#&0R'U'-=S16D*]6G%PA-I/=)NQG
M.A2J24YP3:V;2NCG?%WP]\-^/(8HO$&BV>JK"=T37$8+QG_98<K^!JUX7\(:
M+X*TP:=H6F6VEV08OY-M&%!8]2>Y/N>:V**EUJCA[-R?+VOI]PU1IJ?M5%<W
M>VOWA11161L%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
)44 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>nrbo-20241104.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.8.0.95 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/1/2024 9:40:10 PM-->
<!--Modified on: 11/1/2024 9:40:10 PM-->
<xsd:schema targetNamespace="http://www.neurobopharma.com/20241104" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:us-roles="http://fasb.org/us-roles/2024" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:currency="http://xbrl.sec.gov/currency/2024" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:naics="http://xbrl.sec.gov/naics/2024" xmlns:srt-roles="http://fasb.org/srt-roles/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt="http://fasb.org/srt/2024" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:exch="http://xbrl.sec.gov/exch/2024" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:sic="http://xbrl.sec.gov/sic/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:stpr="http://xbrl.sec.gov/stpr/2024" xmlns:attributeFormDefault="unqualified" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:nrbo="http://www.neurobopharma.com/20241104" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:dtr="http://www.xbrl.org/2009/dtr" xmlns:cef="http://xbrl.sec.gov/cef/2024" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.neurobopharma.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="nrbo-20241104_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="nrbo-20241104_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>nrbo-20241104_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.8.0.95 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/1/2024 9:40:10 PM-->
<!--Modified on: 11/1/2024 9:40:10 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink">
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Adress Line Two</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, State or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Written Communications</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Soliciting Material</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Issuer Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>nrbo-20241104_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.8.0.95 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/1/2024 9:40:10 PM-->
<!--Modified on: 11/1/2024 9:40:10 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="nrbo-20241104.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.neurobopharma.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <presentationLink xlink:role="http://www.neurobopharma.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType_638660940102499982" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentType_638660940102499982" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_638660940102499982" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_638660940102499982" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_638660940102499982" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityFileNumber_638660940102499982" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_638660940102499982" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityRegistrantName_638660940102499982" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_638660940102499982" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_638660940102499982" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_638660940102499982" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_638660940102499982" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_638660940102499982" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_638660940102499982" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2_638660940102499982" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressAddressLine2_638660940102499982" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_638660940102499982" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_638660940102499982" order="9" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_638660940102499982" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_638660940102499982" order="10" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_638660940102499982" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_638660940102499982" order="11" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_638660940102510254" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_CityAreaCode_638660940102510254" order="12" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_638660940102510254" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_LocalPhoneNumber_638660940102510254" order="13" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications_638660940102510254" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_WrittenCommunications_638660940102510254" order="14" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial_638660940102510254" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_SolicitingMaterial_638660940102510254" order="15" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer_638660940102510254" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_PreCommencementTenderOffer_638660940102510254" order="16" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer_638660940102510254" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer_638660940102510254" order="17" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_638660940102510254" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_Security12bTitle_638660940102510254" order="18" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_638660940102510254" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_TradingSymbol_638660940102510254" order="19" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_638660940102510254" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_SecurityExchangeName_638660940102510254" order="20" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_638660940102520437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_638660940102520437" order="21" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_638660940102520437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityCentralIndexKey_638660940102520437" order="22" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_638660940102520437" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_AmendmentFlag_638660940102520437" order="23" use="optional" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46223379690576">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Nov. 04, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov.  04,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37809<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">NEUROBO PHARMACEUTICALS, INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">47-2389984<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">545 Concord Avenue<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Adress Line Two</a></td>
<td class="text">Suite 210<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cambridge<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02138<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">857<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">702-9600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">NRBO<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001638287<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( ,I#9%D'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " #*0V19FK(ZB^X    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+/
M2L0P$(=?17)OIVD7#Z&;B^))07!!\1:2V=U@\X=DI-VW-ZV[740?P&-F?OGF
M&YA>1Z%#PN<4(B:RF&\F-_@L=-RR(U$4 %D?T:E<EX0OS7U(3E%YI@-$I3_4
M :%MFEMP2,HH4C #J[@2F>R-%CJAHI#.>*-7?/Q,PP(S&G! AYXR\)H#D_/$
M>)J&'JZ &4:87/XNH%F)2_5/[-(!=DY.V:ZI<1SKL5MR90<.;T^/+\NZE?69
ME-=8?F4KZ!1QRRZ37[N[^]T#DVW3;BK.JV:SXYWH&M'R]]GUA]]5V 5C]_8?
M&U\$90^_[D)^ 5!+ P04    " #*0V19F5R<(Q &  "<)P  $P   'AL+W1H
M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03<VEVV[29A.U.
M'X416(UL>621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X
M8-DOV]:[MR_>X%<R)!%!,!FGK_# "J5,7K5::0##.'W)$Q+#W(*+"$MX%,O6
M7.!;&B\CUNJTV]U6A&ELH1A'9&!]7BQH0-!445IO7R"TY1\S^!7+5(UEHP$3
M5T$FN8BT\OELQ?S:WCYES^DZ'3*!;C ;6"!_SF^GY$Y:B.%4PL3 :F<_5FO'
MT=)(@(+)?90%NDGVH],5"#(-.SJ=6,YV?/;$[9^,RMIT-&T:X./Q>#BVR]*+
M<!P$X%&[GL*=]&R_I$$)M*-IT&38]MJND::JC5-/T_=]W^N;:)P*C5M/TVMW
MW=..B<:MT'@-OO%/A\.NB<:KT'3K:28G_:YKI.D6:$)&X^MZ$A6UY4#3( !8
M<';6S-(#EEXI^G64&MD=N]U!7/!8[CF)$?[&Q036:=(9EC1&<IV0!0X -\31
M3%!\KT&VBN#"DM)<D-;/*;50&@B:R('U1X(AQ=RO_?67N\FD,WJ=?3K.:Y1_
M::L!I^V[F\^3_'/HY)^GD]=-0LYPO"P)\?LC6V&')VX[$W(Z'&="?,_V]I&E
M)3+/[_D*ZTX\9Q]6EK!=S\_DGHQR([O=]EA]]D]';B/7J<"S(M>41B1%G\@M
MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7
MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V<
M/!T3$LV4"P9!AI<D)A*I.7Y-2!/^*Z7:_IS30/"4+R3Z2I&/:;,CIW0FS>@S
M&L%&KQMUAVC2/'K^!?F<-0H<D1L= F<;LT8AA&F[\!ZO)(Z:K<(1*T(^8ADV
M&G*U%H&V<:F$8%H2QM%X3M*T$?Q9K#63/F#([,V1=<[6D0X1DEXW0CYBSHN0
M$;\>ACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0'
MHYI9";V$5FJ?JH<T/J@>,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y
M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RS<C'5*^3*=@Y
MG\#L_6@^GO'M^MDDA*^:62TC%I!+@;-!)+C\B\KP*L0)Z&1;)0G+5--E-XH2
MGD(;;NE3]4J5U^6ON2BX/%ODZ:^A=#XLS_D\7^>TS0LS0[=R2^JVE+ZU)CA*
M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D*
MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-#
MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B
M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P
MOFH]M!5.S_Y9K<B?#!%.%@L22&.4%Z9*HO,94[[G*TG$53B_13.V$I<8O./F
MQW%.4[@2=K8/ C*YNSFI>F4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W
MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2
MD 83 <V4R43P H)DIAR F/H+O?(,N2D5SJT^.7]%+(.&3E[2)1(4BK ,!2$7
M<N/O[Y-J=XS7^BR!;814,F35%\I#B<$],W)#V%0E\Z[:)@N%V^)4S;L:OB9@
M2\-Z;ITM)__;7M0]M!<]1O.CF> >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F
M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+
M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5
M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0    (
M ,I#9%G[.%"4<P0  %H1   8    >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
MG9AM;^HV%,>_BI5-TR;1DH2GT %22NDNNBUE0'>E37MA$@-6$SO7<:!\^QT'
MFK#=<.#N#7FR__GYG.._'7H[J=[2#6.:O,>12/O61NODKEY/@PV+:7HK$R;@
MR4JJF&JX5.MZFBA&P[Q3'-5=VV[78\J%->CE]Z9JT).9CKA@4T72+(ZIVM^S
M2.[ZEF-]W)CQ]4:;&_5!+Z%K-F?Z-9DJN*H7*B&/F4BY%$2Q5=_RG;M[MV4Z
MY"W^X&R7GIP3,Y2EE&_F8ASV+=L0L8@%VDA0.&S9D$6140*.KT=1JWBGZ7AZ
M_J'^F \>!K.D*1O*Z L/]:9O>18)V8IFD9[)W2=V'% .&,@HS7_)[M"VV;1(
MD*5:QL?.0!!S<3C2]V,@3CLX9SJXQPYNSGUX44[Y0#4=])3<$65:@YHYR8>:
M]P8X+DQ6YEK!4P[]].!!!AD$61,J0C(2FNL]&8M#MB%JO;J&EYBF]> H>'\0
M=,\(3N3VEMC-&G%MM_GO[G5@*P#= M#-]1K_#Y#\Y2]3K2"Y?U>Q'K2;U=JF
MXN_2A :L;T%)ITQMF37XZ0>G;?^*D#<*\@:F7I(O]@FK@L.[>S>?$8AF =&\
M#F+*%)<F@B&!0JGDP97RQ.:9O93:5L'60A6/V7SD$2.3+%XR546%:]BV<]/H
M>'87X6D7/.UK>&9LS4U)0= F-*Z,%*XS&;W.7NY?R/23/WOVAZ/7Q7CH/\UK
M9#P9WB*<G8*S<PWG6 12)5+E\Z!&YAK22J0B0YD)K?9P#"OA<?&'$4+H%83>
M-80+^D[&(50?7_'@,%W/YQE7;'9NW(;7[7I8X74+O.XU>'X8PJQ/:Q\GY G:
MD1=1&35<L=5L0;Q-0D+B;YG(&(+IV*4YV]\)6G(N=K+2G7'%><:A2ES'QOA.
M%@_GN_B&Y@I*<"%WU4L'+C>D\5+Q<(T&KUPX'-3=OX$K)LA4R2T7066:+V@^
M^QA:N3(XN+?_%VTJ4TTC\B=/SL[:"XJVZS0\C*U<,!S<Y_,<^K##.X^""WBM
M#@92K@X.;NU/,H"83#=28,O#!9&.[=YTVS9:[N7ZX.#&_D5QK9F P,1Q)HZ6
MEE92X4(K&J5HD9=+@8/;]5Q&/.":BS5YAO)6G$:5/+C*19[2^!W<IZ>*W000
M'@;SZ[#Y82)DBKRL5F?RA^M=)"L]W\$M^ANR<9IF0'81$)>]!.B69N_BUKS@
M&C9"<D4<]^?E+V3.@@SJ;5^YK<653'W"6CO7,GBKD80JLJ51QLB/]BWLET@"
MPTTW5*'8Y1K@XJ:]4#0TY3??QTM967P7!":S^Q>,Y.1+ 3?GCXB1T7NPH6+-
MSN[?+@A-_/F#_SO&5#J]>Y73CV*FUB9*OX&"WA@'2:BHSBTN>+'>2J-W<9\^
MH@UA+B@PVC%,@W?RF55#X5(VE%6[X;D>YOQNZ?PN;MH^S,\PGZ./$5U7\N "
M9X-4/_E2-O\Z/%.3EI1$; 5"]FT'=-7A0_YPH662?SPOI89/\?QTPR@8AFD
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M J<11S &P %#TG1X#SY['R73>RHY_U=3_ 102P,$%     @ RD-D69>*NQS
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M"Q4&L&]R( DNR94;4EWI>::W=Y-[2:AU[D&P]_ :C1W-CQ^W_ %02P,$%
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MO-9.&G_FB^$_7G\!4$L! A0#%     @ RD-D60=!36*!    L0   !
M         ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " #*0V19
MFK(ZB^X    K @  $0              @ &O    9&]C4')O<',O8V]R92YX
M;6Q02P$"% ,4    " #*0V19F5R<(Q &  "<)P  $P              @ ',
M 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( ,I#9%G[.%"4<P0
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M2P$"% ,4    " #*0V19)!Z;HJT   #X 0  &@              @ 'G$0
M>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " #*0V1999!Y
MDAD!  #/ P  $P              @ ',$@  6T-O;G1E;G1?5'EP97-=+GAM
7;%!+!08     "0 ) #X"   6%      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="nrbo-20241104x8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurobopharma.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>nrbo-20241104.xsd</File>
    <File>nrbo-20241104_lab.xml</File>
    <File>nrbo-20241104_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" original="nrbo-20241104x8k.htm">nrbo-20241104x8k.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>nrbo-20241104x8k001.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "nrbo-20241104x8k.htm": {
   "nsprefix": "nrbo",
   "nsuri": "http://www.neurobopharma.com/20241104",
   "dts": {
    "schema": {
     "local": [
      "nrbo-20241104.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "nrbo-20241104_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "nrbo-20241104_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "nrbo-20241104x8k.htm"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 24,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 23
   },
   "report": {
    "R1": {
     "role": "http://www.neurobopharma.com/role/DocumentDocumentAndEntityInformation",
     "longName": "00090 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "Duration_11_4_2024_To_11_4_2024_0HM4nUvhIk6dfCUaU79l4A",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrbo-20241104x8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_11_4_2024_To_11_4_2024_0HM4nUvhIk6dfCUaU79l4A",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nrbo-20241104x8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.neurobopharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.neurobopharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Document and Entity Information [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.neurobopharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.neurobopharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.neurobopharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.neurobopharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Adress Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.neurobopharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.neurobopharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.neurobopharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.neurobopharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.neurobopharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.neurobopharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.neurobopharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.neurobopharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.neurobopharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.neurobopharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.neurobopharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.neurobopharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.neurobopharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.neurobopharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.neurobopharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.neurobopharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.neurobopharma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001558370-24-014184-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-24-014184-xbrl.zip
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M8WV?TOS%,.>(=.ELMB#99T2QIEN3SF+.*EM3L&E%EA)7G?58[#)7*-K6@-Z
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M8;^/<X;79]4%@4\_R=0>2CG/[^8%557S(]I_VJYCN[>9F@P*6E?D>2E/BW7
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M]:"%1(G/047JFOQ2YMS'XLZV!Z8P(-'MGH")!7:6,V%-JR1R?.%8:U]PK?W
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MA#D(&];9^6V]?7I4$[J=OJOHE7@9@(:Z@ +MT#-N=]$ ^^@>.Q%!_\OG>%Y
M WK)0H\=#?/+AV^L4+B>0/]KZ-F/QU>)!H_UZH2IFC^T3B#^J.OUPXN#SJ$W
M[M7<PV&\H[?9VC_]P R3U<8?A6'F ^Q4P3_<;I,JJ33F.SWF%GAJ.#SI*J=%
M%?.<6SWV^\6P>M=,3B'M] AJXL#$=[&R0B?8OR4A.CZN/I&D_]&"Q0W7I.%W
M@O0Q,E@:'A3?PB1+V"DN<SER=H!@" 0PUZ5+I%W?&X8]&L4?T+PY'""36+8;
M'Z\;+^'SA06'F4_/,)?0-A4;98^-5MACJ_GI-] ;T'U S^>E^9/QBH"H<^(S
MST>?;YLN$DP_GVD]A]8W\+T$H.J+Z9?HKS=<38OW[*3@'3+HJC%P,WG@N(7#
M\/*\'5S85_N7AGXW.!]=#5]_&>VCL$/#^HE0TZSTA1K"?I! VP/Y)PXQZ,V)
MKL<6FJ* L%K 04F:+KT/CT5(4'RM%64.UI<SIIW3NQQ9#JX+8X$2GP!>X#O0
M*M@U:#8&-@QZFB&M3&^P,[%O!G&"KOG8*I>TC2>K7+-Z(I=P_._PS4KYY 67
M)+W1'58+KZEZKFWSZK$L^O-?F4@=-FZ!OR/7I(MQGE].H9BYQRR)$(ILK%W"
MQ8% ;,%$4<;.$(^#Q')3U)R4&F[ER4#H!8<HOCT-S?R]-SGWX,^[E6TNT_4U
MKF!+EGNMDFJ9LE721$NT-%DM6EK)E!3-LL2"(/)JL520D@7794OAPLLFF.$,
M"A*,YIEUUH(\6+ QY5=!BA]I0S!#P43J+-J#V@A)'RDY7HAO:GA4H[UNY\FK
MJ>N3R&'\ZV?[<EJD&SGQ3HR#&JK9@>%X0>23W/*VZ/R(@M"VQK]_0MIJ(#NE
MQXAE;VG9A>8CW]OWT!F[O-<@$7,K@UW4<(T<VJ83W%9J,.V M1Y$,"=BF![I
MSET0-8)A0L:N"QK0H#,H_8!-OF1V4PS;AS0 ZM 4'?9 ,1-2H]X. Q0./6Z
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M)Q/<>[:Y.)=@DBR0USUS#+]Z8=_Y^O]02P,$%     @ RD-D62M@$4M]+@
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M0Z80G9L5@\_9KS.V31-T:5ZP\E&NTB>Y7Y]=&J&.*E +ML;=*I(QZ\C(:-)
M/D,VU^DO,H?>[1;QR=U+I">68(3A9./J93@>+]NA#0ZPV-[W84 LJU^+3-9Y
MN:I^LGGR\1@UP6,GZ9KY\Y"DDO4FW6BXQ9S"DZ6*8I[/N^JE!D$[H=R4*&98
M+P[P5V4%!]"H] V RGAOI<;N!IT7CQ.);IM5K^L)/G7--)JJE+K,5+%?*+:X
MVF#M?S$FH:H ']RS9\ !NC51;2B?\;L*Q $4W6]U1#VF\D*MCJ'AEQ;N<HG
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M::&*E?;NPO0U_])A^;>IHHVG3[;+KK1WVRTOGH*<$;PVI,Q]-X^^YGC<^H:
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MQ%S"X;3Z)\,S:(NSO7X++P=.%X&*MI/.P=LOP\;2!?I!-<0#:QH&#&_DIM4
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MBSL1.*'%L#P_>*+=R7K.N3=5*C3-;Q3<;E]2 H\@]RZ\EQ'M37 *9<;D@UV
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ML&?P0I8\6WE:?J?!0<JXUJ(@&NK[". !O9YHOJ#T 1@XFW*UP31KS@AN0^(
MU24:MREIYF^7ZT]55) GAQR-=ER(,<B:GOX"139SGJW.E1&E4UN*.@VA!PD>
MJ*%G)_Z"+]7>O@#<2AXBGJQ3X)CGH]OD EVSD8OW )DXDL-;$H[.IDYZME @
MOD(A\4;IJG9J2I0?@MH,X76$MW["9>/.E+IWT_N!3V8BZLRPMA_FKZG LQLB
MO*R^&>O>(#GF1@#0KA VS_4O?+5\=,6^ACA'#/5G-=JWQ0:['J\&.&NDR!I5
MQ$N0*JLSGIXDJCH*)TCVUJ"2UCY&[R B?^P$6Y;_CO)^]S6>ZFF>RE-R# GC
MA>8'-\E(;'H#.ZLUZ8G> D9!U<0IKMNP7]C,VN_@U&58L*>SGG^Z97YH/4&
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M_P!02P$"% ,4    " #*0V19PY9=+WD#  !@#   $0              @ $
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52P4&      8 !@"2 0  (V8

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>nrbo-20241104x8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="nrbo-20241104.xsd" xlink:type="simple"/>
    <context id="Duration_11_4_2024_To_11_4_2024_0HM4nUvhIk6dfCUaU79l4A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
        </entity>
        <period>
            <startDate>2024-11-04</startDate>
            <endDate>2024-11-04</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="Duration_11_4_2024_To_11_4_2024_0HM4nUvhIk6dfCUaU79l4A"
      id="Tc_Q3E9bgYu3EmakLr16uCgFg_1_1">0001638287</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="Duration_11_4_2024_To_11_4_2024_0HM4nUvhIk6dfCUaU79l4A"
      id="Tc_D7wVMaGpRk-PWAP_nRb-TA_2_1">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="Duration_11_4_2024_To_11_4_2024_0HM4nUvhIk6dfCUaU79l4A"
      id="Narr_9VkLvaFZTUas3CmLbb6X_w">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_11_4_2024_To_11_4_2024_0HM4nUvhIk6dfCUaU79l4A"
      id="Narr_gcPPrxnD-0-tDaq3TrbLsQ">2024-11-04</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="Duration_11_4_2024_To_11_4_2024_0HM4nUvhIk6dfCUaU79l4A"
      id="Narr_HIy_5AwW-E-shKtXAv5_rw">NEUROBO PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_11_4_2024_To_11_4_2024_0HM4nUvhIk6dfCUaU79l4A"
      id="Tc_yg5R0fhpUkG-XfwYIzXtCw_1_0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="Duration_11_4_2024_To_11_4_2024_0HM4nUvhIk6dfCUaU79l4A"
      id="Tc_CZg63igVd0CHyAxJ7qND9w_1_2">001-37809</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_11_4_2024_To_11_4_2024_0HM4nUvhIk6dfCUaU79l4A"
      id="Tc_GkPc3mDfLEu5B_Bx16S1cg_1_4">47-2389984</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_11_4_2024_To_11_4_2024_0HM4nUvhIk6dfCUaU79l4A"
      id="Narr_dAJP1cQoE0WbF9LLtRBYiA">545 Concord Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="Duration_11_4_2024_To_11_4_2024_0HM4nUvhIk6dfCUaU79l4A"
      id="Narr_VuyVD8I5LUqOZO3dsZSV8Q">Suite 210</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_11_4_2024_To_11_4_2024_0HM4nUvhIk6dfCUaU79l4A"
      id="Narr_lHnbpQkYZkWr8wVE0k_cZA">Cambridge</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_11_4_2024_To_11_4_2024_0HM4nUvhIk6dfCUaU79l4A"
      id="Narr_0XFEjWajuEaqinTDZaXvhg">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_11_4_2024_To_11_4_2024_0HM4nUvhIk6dfCUaU79l4A"
      id="Tc_nEFDXnC7dUqWU2B78DSbQA_1_2">02138</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_11_4_2024_To_11_4_2024_0HM4nUvhIk6dfCUaU79l4A"
      id="Narr_4aIvJG5xDEKEo4JDGhG_ag">857</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_11_4_2024_To_11_4_2024_0HM4nUvhIk6dfCUaU79l4A"
      id="Narr_wDyLcISaTE6yWlTHeVFrdg">702-9600</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="Duration_11_4_2024_To_11_4_2024_0HM4nUvhIk6dfCUaU79l4A"
      id="Tc_rwncbftdJEeAIp4yg3ncZA_1_0">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="Duration_11_4_2024_To_11_4_2024_0HM4nUvhIk6dfCUaU79l4A"
      id="Tc_f82-05L_SU-RBso3sp46yg_2_0">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="Duration_11_4_2024_To_11_4_2024_0HM4nUvhIk6dfCUaU79l4A"
      id="Tc_zo6R3wnmQ0-kz37bMrW8mw_3_0">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="Duration_11_4_2024_To_11_4_2024_0HM4nUvhIk6dfCUaU79l4A"
      id="Tc_B4Zo1vC75EqOfgtiauhQSw_4_0">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="Duration_11_4_2024_To_11_4_2024_0HM4nUvhIk6dfCUaU79l4A"
      id="Tc_DdptIfPQkESOHD1gTmn7bA_2_0">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_11_4_2024_To_11_4_2024_0HM4nUvhIk6dfCUaU79l4A"
      id="Tc_Nj_Ts2jEbEGUFTGoyhDnGw_2_2">NRBO</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_11_4_2024_To_11_4_2024_0HM4nUvhIk6dfCUaU79l4A"
      id="Tc_wwMg7O69a0-nCLrm6tCqNw_2_4">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_11_4_2024_To_11_4_2024_0HM4nUvhIk6dfCUaU79l4A"
      id="Narr_aRattVQSsUiWBVcbqpQxWw">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
